ランキング価格はじめての方へ
  1. 米国企業
  2. NeuBase Therapeutics, Inc.
  3. Raw

NeuBase Therapeutics, Inc.NBSE

時価総額
$141万
PER
前臨床段階のバイオ医薬品開発の新興企業。PATrOLプラットフォーム由来の遺伝子標的治療候補を展開。2021年4月のVera買収と2022年1月のCMUライセンスでの株式発行、2022年10月に従業員を約60%削減し15名体制。米国中心に展開。
概要財務
サマリーテーブルに戻る
2011年
9月30日		2012年
9月30日		2013年
9月30日		2014年
9月30日		2015年
9月30日		2016年
9月30日		2017年
9月30日		2018年
9月30日		2019年
9月30日		2020年
9月30日		2021年
9月30日		2022年
9月30日
Net loss-5,101,519-1,454,884-5,652,488-9,130,664-15,197,865-25,766,198-23,810,996-13,236,900-26,958,247-17,384,520-25,409,301-33,776,450
Stock-based compensation679,301122431877,75110543
Research and development, Vera acquisition----------3-
Fair Value Adjustment of Warrants--------492,889453,808-950,151-
Depreciation and amortization----1111128,372280,463403,043767,302
Loss on marketable securities-----------25,012-30
Loss on disposal of fixed assets-------1,349-17,814--3,230-31,853-11,439
Equity in losses on equity method investment----10,643-103,143-----262,861-224,534-415,747
Gain on sale of intellectual property-------460,383--316,724-
Amortization of right-of-use assets-----------495,210
Prepaid insurance, other prepaid expenses and current assets--------310,617386,499-264,442666,945-539,245
Long-term prepaid insurance--------338,916-193,666-145,250-
Security deposit-----------253,615-19,600
Other long-term assets----------160,420-160,423
Accounts payable--------962,434-129,088294,54835,142
Increase (Decrease) in Accrued Liabilities--------385,765150,283943,442-85,088
Operating lease liability----------58,899-453,055
Net cash used in operating activities-1,004,527-1,753,829-2,689,687-5,360,132---19,290,972-9,492,423-2,845,488-10,710,071-18,873,684-29,011,966
Purchase of laboratory and office equipment25,01858,42158,421-----455,200716,8201471,711
Purchase of marketable securities----------6015
Sale of marketable securities----------6015
Cash paid for Vera acquisition----------1-
Net cash used in investing activities163,482130,079130,079-3,514,869--88,452528,038-685,225-716,820-2,563,467-471,741
Principal payment of financed insurance--------90,081349,792381,797148,385
Principal payment of finance lease liability----------8,770109,500
Proceeds from Issuance of Common Stock----27-20-83343-
Proceeds from Stock Options Exercised---------171,030112,446868
Net cash (used in) provided by financing activities371217--19-86,264143342-257,017
Net (decrease) increase in cash and cash equivalents--------102221-29,740,724
Cash paid for interest------8,61710,2063,1773,244--
Income Taxes Paid, Net------------
Stock Issued--1122350,000-----2-
Purchases of laboratory and office equipment in accounts payable----------8,295-
Preferred shares in DepYmed received as consideration for sale of intellectual property----------316,724-
Insurance financed through note payable--------213,000365,430391,625-
Right-Of-Use Asset In Exchange For Operating Lease Liability-----------164,613
Deferred offering costs accrued----------160,420-